Effects on major adverse cardiovascular events (MACE) in persons treated with sotagliflozin: Prespecified pooled analyses of the Phase 3 type 2 diabetes program
Abstract
Background: In the SCORED trial that included 10,584 participants with type 2 diabetes (T2D) and chronic kidney disease (CKD), sotagliflozin significantly reduced the incidence of major adverse cardiovascular events (MACE). To further evaluate the cardiovascular effects of sotagliflozin, prespecified MACE-focused meta-analyses were performed using data from 9 additional Phase 3 trials conducted in persons with T2D.
Methods: This patient-level meta-analyses pooled data from 9 Phase 3 trials assessing glycemic control and other cardiometabolic parameters in a total of 5,100 participants. 2,904 participants were treated with sotagliflozin (pooling 200 and 400mg doses), while 2,196 were in an All-Comparators group (pooling placebo, empagliflozin, and glimepiride). Time to first event for 4-point MACE [CV death, nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization for unstable angina) was the prespecified primary analysis. Secondary outcomes included 3-point MACE (omitting unstable angina) and analyses of each MACE component outcome. Time-to-event analyses were conducted using Cox proportional hazards models for the first occurrence of any adjudication-confirmed event.
Results: There were 98 4-point MACE events and 96 3-point MACE events across the dataset. Event rate of 4-point MACE was 1.6 events per 100 patient-years (PY) in the sotagliflozin group compared with 2.2 events per 100 PY in the All-Comparators group. Sotagliflozin was associated with a 39%…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 15,000 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.